All data are based on the daily closing price as of June 6, 2025
s

Samsung Biologics

207940.KO
735.62 USD
3.34
+0.46%

Overview

Last close
735.62 usd
Market cap
52.36B usd
52 week high
761.21 usd
52 week low
522.84 usd
Target price
736.14 usd

Valuation

P/E
N/A
Forward P/E
49.7512
Price/Sales
14.8052
Price/Book Value
6.4296
Enterprise Value
53.49B usd
EV/Revenue
14.8326
EV/EBITDA
31.6972

Key financials

Revenue TTM
3.61B usd
Gross Profit TTM
1.90B usd
EBITDA TTM
1.62B usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
11.83B usd
Net debt
N/A usd

About

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and regulatory support services; and quality, biosafety and analytical testing services, as well as manufactures drug substance. In addition, it engages in the development and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
  • Symbol
    207940.KO
  • Exchange
    KO
  • Isin
    KR7207940008
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Mr. John Chongbo Rim
  • Headquarter
    Incheon
  • Web site
    https://samsungbiologics.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top